Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()

AIM: Sunitinib has shown benefit in patients with imatinib (IM)–resistant gastrointestinal stromal tumor (GIST). However, its advantages are somewhat diminished because of associated toxicities. Herein, we clarify the efficacy and safety of fractioned dose regimen of sunitinib by a pharmacokinetic a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Transl Oncol
Main Authors: Chen, Yen-Yang, Yeh, Chun-Nan, Cheng, Chi-Tung, Wu, Chao-En, Chiang, Kun-Chun, Chen, Tsung-Wen, Wang, Chih-Chi, Chen, Jen-Shi, Yeh, Ta-Sen
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press 2014
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4225693/
https://ncbi.nlm.nih.gov/pubmed/25389456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2014.08.004
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares